On March 18, Fosun Pharma announced that the MPP (Medicine Patent Pool Organization) granted the company’s holding subsidiary Fosun Pharma Industry the use of relevant patents and know-how to produce the oral novel coronavirus treatment drug “Nirmatrelvir” ” of the generic and licensed product “Nematavir/Ritonavir Combination” and a non-exclusive license to commercialize the licensed product and related rights in the Territory. The above-mentioned production includes the production of nelmatevir raw materials (drugs) and finished drugs (preparations), as well as the production of nelmatevir/ritonavir combinations. This license is a non-exclusive license; the licensed area is India, Pakistan, Cote d’Ivoire and other 95 low- and middle-income countries, excluding China.
Source: Beijing Daily Client
Process Editor: U022